Medicare to Negotiate Botox and 14 Other High-Cost Drugs This Year

Medicare announced the next round of price negotiations under the Inflation Reduction Act, targeting Botox plus 14 other expensive drugs (including Trulicity) used for cancer, diabetes, Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. The negotiated prices, affecting about $27 billion in Medicare Part B and Part D spending, will take effect in 2028. Drugmakers can opt out, but historically none have; Part B covers clinic-administered drugs and Part D covers prescriptions.